QHSLab (OTCQB: USAQ) Rolls Out Breakthrough Pediatric Screening Tool Linking Allergies and Mental Health
QHSLab (OTCQB: USAQ) has launched its innovative Pediatric Health Assessment tool with a major pediatric group in Texas. This digital screening solution uniquely integrates behavioral health screening with allergy and asthma control metrics, addressing the connection between immune and mental health in children.
The assessment combines evidence-based behavioral health screeners (PSC-17 and SDQ Prosocial scale) with allergy control metrics (CARAT), creating a comprehensive evaluation platform. The tool screens for anxiety, depression, ADHD, sleep issues, and physical health factors, enabling pediatricians to provide more precise care during back-to-school checkups.
QHSLab has received IRB exemption for observational research to study the tool's population health impact, particularly focusing on the relationship between allergy management and behavioral screening results. This initiative positions the company for potential collaborations with pharmaceutical companies, payers, and public health systems.
QHSLab (OTCQB: USAQ) ha lanciato il suo innovativo strumento di Valutazione della Salute Pediatrica insieme a un importante gruppo pediatrico del Texas. Questa soluzione digitale di screening integra in modo unico la valutazione della salute mentale con indicatori di controllo di allergie e asma, considerando il legame tra sistema immunitario e benessere mentale nei bambini.
La valutazione combina strumenti di screening comportamentale basati su evidenze (PSC-17 e la scala Prosociale dell'SDQ) con metriche di controllo delle allergie (CARAT), creando una piattaforma di valutazione completa. Lo strumento rileva ansia, depressione, ADHD, disturbi del sonno e fattori di salute fisica, consentendo ai pediatri una cura più mirata durante le visite di ritorno a scuola.
QHSLab ha ottenuto l'esenzione IRB per la ricerca osservazionale finalizzata a studiare l'impatto sulla salute della popolazione dello strumento, con particolare attenzione alla relazione tra gestione delle allergie e risultati degli screening comportamentali. Questa iniziativa apre la strada a possibili collaborazioni con aziende farmaceutiche, assicuratori e sistemi di sanità pubblica.
QHSLab (OTCQB: USAQ) ha lanzado su innovadora herramienta de Evaluación de la Salud Pediátrica con un importante grupo pediátrico de Texas. Esta solución digital de cribado integra de forma única la evaluación de la salud conductual con métricas de control de alergias y asma, abordando la conexión entre el sistema inmunitario y la salud mental en niños.
La evaluación combina evaluaciones conductuales basadas en la evidencia (PSC-17 y la escala Prosocial del SDQ) con métricas de control de alergias (CARAT), creando una plataforma de evaluación integral. La herramienta detecta ansiedad, depresión, TDAH, problemas de sueño y factores de salud física, permitiendo a los pediatras ofrecer una atención más precisa en los chequeos de regreso a clases.
QHSLab ha obtenido la exención IRB para investigación observacional destinada a estudiar el impacto en la salud poblacional de la herramienta, con especial atención a la relación entre el manejo de las alergias y los resultados de los cribados conductuales. Esta iniciativa posiciona a la compañía para posibles colaboraciones con farmacéuticas, aseguradoras y sistemas de salud pública.
QHSLab (OTCQB: USAQ)는 텍사스의 주요 소아과 그룹과 함께 혁신적인 소아 건강 평가 도구를 출시했습니다. 이 디지털 선별 도구는 행동 건강 선별과 알레르기·천식 관리 지표를 독창적으로 통합하여 아동의 면역과 정신 건강 간 연관성을 다룹니다.
평가는 근거 기반 행동 건강 선별 도구(PSC-17 및 SDQ의 Prosocial 척도)와 알레르기 관리 지표(CARAT)를 결합해 포괄적인 평가 플랫폼을 제공합니다. 이 도구는 불안, 우울, ADHD, 수면 문제 및 신체 건강 요인을 선별하여 소아과 의사가 새 학기 건강검진에서 보다 정확한 진료를 제공할 수 있게 합니다.
QHSLab는 이 도구의 인구 보건 영향 연구를 위한 관찰연구 IRB 면제를 받았으며, 특히 알레르기 관리와 행동 선별 결과 간 관계에 주목하고 있습니다. 이 이니셔티브는 제약사, 지급자, 공공 보건 시스템과의 잠재적 협력을 위한 기반을 마련합니다.
QHSLab (OTCQB: USAQ) a déployé son innovant outil d'Évaluation de la Santé Pédiatrique avec un important groupe pédiatrique du Texas. Cette solution de dépistage numérique intègre de façon originale le dépistage de la santé comportementale aux indicateurs de contrôle des allergies et de l'asthme, prenant en compte le lien entre immunité et santé mentale chez l'enfant.
L'évaluation associe outils de dépistage comportemental fondés sur des preuves (PSC-17 et l'échelle Prosociale du SDQ) aux métriques de contrôle des allergies (CARAT), offrant une plateforme d'évaluation complète. L'outil dépiste l'anxiété, la dépression, le TDAH, les troubles du sommeil et des facteurs de santé physique, permettant aux pédiatres d'offrir des soins plus ciblés lors des bilans de rentrée scolaire.
QHSLab a obtenu une exemption IRB pour une recherche observationnelle visant à étudier l'impact de l'outil sur la santé des populations, en se concentrant notamment sur la relation entre la prise en charge des allergies et les résultats des dépistages comportementaux. Cette initiative positionne l'entreprise pour d'éventuelles collaborations avec des laboratoires pharmaceutiques, des payeurs et des systèmes de santé publique.
QHSLab (OTCQB: USAQ) hat sein innovatives Pädiatrisches Gesundheitsassessment gemeinsam mit einer großen Kinderarztgruppe in Texas eingeführt. Diese digitale Screening-Lösung verknüpft auf einzigartige Weise Verhaltensgesundheits-Screenings mit Messgrößen zur Kontrolle von Allergien und Asthma und geht damit auf die Verbindung zwischen Immunsystem und psychischer Gesundheit bei Kindern ein.
Das Assessment vereint evidenzbasierte Verhaltens-Screenings (PSC-17 und die Prosocial-Skala des SDQ) mit Allergiekontrollmetriken (CARAT) und schafft eine umfassende Bewertungsplattform. Das Tool erfasst Angst, Depression, ADHS, Schlafprobleme und körperliche Gesundheitsfaktoren und ermöglicht Pädiatern eine präzisere Betreuung bei den Schulbeginn-Untersuchungen.
QHSLab hat eine IRB-Befreiung für Beobachtungsforschung erhalten, um die Auswirkungen des Tools auf die Bevölkerungsgesundheit zu untersuchen, mit besonderem Fokus auf die Beziehung zwischen Allergiemanagement und Ergebnissen der Verhaltensscreenings. Diese Initiative positioniert das Unternehmen für mögliche Kooperationen mit Pharmafirmen, Kostenträgern und öffentlichen Gesundheitssystemen.
- First-of-its-kind integrated pediatric screening tool combining mental and immune health assessment
- Secured partnership with major multi-location pediatric group in Texas
- Received IRB exemption for observational research, enabling valuable data collection
- Positioned for recurring revenue in a reimbursement-friendly market
- None.
Back-to-School Season Just Got Smarter
The Pediatric Health Assessment empowers parents and providers to uncover hidden health or behavioral issues that may affect academic and social success.
QHSLab’s platform delivers critical insights at the perfect time for pediatricians to support whole-child wellness as families prepare for the new academic year.
West Palm Beach, FL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a leading provider in digital medicine solutions for primary care and specialty practices, today announced the recent launch of its new Pediatric Health Assessment with a prominent, multi-location pediatric group in Texas. The assessment is now live across the group’s practices, aligning with the annual surge in back-to-school visits and well-child checkups.
The Pediatric Health Assessment is a first-of-its-kind digital screening tool that integrates evidence-based behavioral health screeners (including the PSC-17 and SDQ Prosocial scale), asthma/allergy control metrics (CARAT), over-the-counter allergy medication use, and help-seeking behaviors into a single, streamlined digital experience.
“This tool goes far beyond traditional checklists,” said Troy Grogan, President and CEO of QHSLab. “We’re giving pediatricians real-time insight into how allergy symptoms, behavioral and developmental issues, as well as sleep problems overlap. This is especially powerful as kids return to classrooms — we’re helping providers and parents catch things early before they escalate. This timely launch represents a significant commercial milestone for QHSLab”
The tool’s unique value lies in its interconnected clinical data framework — screening children for internalizing and externalizing symptoms, attention difficulties, social skill strengths, suicide or self-harm risk, and physical health drivers like poorly managed allergic rhinitis or asthma. This holistic approach enables providers to deliver precision care, providing QHSLab a differentiated position in the pediatric digital health market.
“Pediatricians are often the first to see signs of anxiety, depression, ADHD, or sleep disturbances, but they rarely have time to assess all these factors in a single visit,” said Dr. Juan Oms, Psychiatrist and Medical Adviser to QHSLab. “This tool brings together behavioral and physical health in a meaningful way, improving early detection for these often complex health issues, while respecting provider time and practice workflow.”
QHSLab has received IRB exemption to carry out observational research to evaluate the tool’s population health impact. The study will investigate how the management of allergy symptoms—particularly those linked to poor sleep and medication misuse—relates to behavioral screening results. This study is part of QHSLab’s broader data strategy to validate correlations between immune health and psychosocial risk factors, reinforcing the clinical and economic value of comprehensive screening tools that support early intervention.
“The long-term value of this dataset should excite investors,” said Dr. Marcos Sánchez-González, MD, PhD, Vice President of Medical and Scientific Affairs. “This opens the door to real-world evidence showing the interaction between immune health and mental health in children — data that could drive collaborations with pharma, payers, or public health systems focused on integrated care.”
For QHSLab (USAQ), the pediatric product line expands the company’s recurring revenue model in a high-demand, reimbursement-friendly market. With the rising public health urgency around youth mental health, the product is well-positioned for broader adoption, strategic partnerships, and future licensing opportunities
Pediatrics practices interested in learning more can visit https://www.qhslab.com/learning-lab/blog/smarter-pediatric-screening-tools-introducing-qhslabs-digital-health-assessment-for-children or contact QHSLab directly at hello@qhslab.com.
About QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a digital health technology leader providing preventive screening, assessment, and workflow solutions for primary care. Its tools help practices identify, document, and manage underdiagnosed chronic and behavioral conditions efficiently and profitably.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ
What is QHSLab's new Pediatric Health Assessment tool?
How does USAQ's pediatric screening tool benefit healthcare providers?
What markets is QHSLab (USAQ) targeting with its pediatric assessment tool?
What research is QHSLab conducting on their pediatric assessment platform?
How does QHSLab's tool address back-to-school health screening needs?
